Skip to content
Search

Latest Stories

India-made drugs dominate illegal imports in Switzerland

India-made drugs dominate illegal imports in Switzerland

A LARGE number of illegally imported drugs in Switzerland are found to have been sent from India, a Swiss government agency said on Monday (21).

They included medicines connected with Covid-19, ivermectin and hydroxychloroquine as also erectile stimulants.

In its annual update, the Swiss Agency for Therapeutic Products (Swissmedic) said it, along with customs authorities, seized 9,421 packages containing illegally imported medicinal products during 2021, which was significantly higher than 6,733 such packages in 2020.

The majority of the products seized were potency preparations and accounted for around 77 per cent of the confiscated packages.

Other preparations included prescription-only medicines, such as hormones and anti-inflammatories (17 per cent) or sleeping tablets and tranquillisers (five per cent).

Around 150 of the seized packages were connected with the Covid-19 pandemic. These contained prohibited quantities of prescription-only medicinal products, including anti-parasitics containing ivermectin, medicinal products containing hydroxychloroquine or antibiotics from India.

Swissmedic said Poland has overtaken south Asian nations to become the first European country to top the country-of-origin rankings.

However, the contents of the packages of potency preparations from Poland that were seized were all erectile stimulants manufactured in India.

Swissmedic suspects that new illegal distribution channels have been set up after the authorities successfully shut down the transit route via Singapore in October 2020 as part of an internationally coordinated operation.

India directly accounted for 12 per cent of total seized packages, down from 20 per cent in 2022 and from 43 per cent in 2019.

"Half of the illegally sold preparations do not contain what they claim to contain! Taking medicinal products that have been ordered without a prescription or with a sham online prescription is dangerous to health," Swissmedic said.

(PTI)

More For You

Netflix buyback

The company ended Q1 with $12.3 billion in cash, partly because buybacks were paused during the Warner Bros process

Getty Images

Netflix approves $25 billion buyback after scrapping Warner Bros bid

Highlights

  • Netflix board approved a $25bn share repurchase on 22 April, with no expiry date.
  • The move follows Netflix abandoning its $83bn bid for Warner Bros' streaming and studio assets.
  • Netflix stock has fallen more than 10 per cent since weak Q2 guidance, closing at $93.24 on 22 April.
Netflix has approved a $25 billion share buyback programme, using capital it had kept aside for its failed bid to buy Warner Bros.
The board gave the green light on 22 April, with the decision disclosed in an SEC filing the next day.
There is no expiry date on the programme. It comes on top of an existing December 2024 buyback that still had $6.8 billion left as of 31 March.

Earlier this year, Netflix pulled out of an $83 billion deal to acquire Warner Bros' streaming and studio assets after Paramount Skydance made a rival bid for Warner Bros. Discovery. Paramount then paid Netflix a $2.8 billion exit fee.

Co-CEOs Ted Sarandos and Greg Peters had already said the company would restart share buybacks once the deal was off.

Netflix shares have had a rough ride. They hit an all-time high of $134.12 in June 2025, then fell more than 40 per cent when the Warner Bros deal was announced.

Keep ReadingShow less